SCHEMBL8260909

SCHEMBL8260909

COCCOCc1cccc([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.54
MAOB P27338 2/20 0.52
MAOA P21397 1/20 0.52
F2RL3 Q96RI0 1/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
RECQL P46063 1/20 0.49
LMNA P02545 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA1D P25100 1/20 0.48
ADRA1A P35348 1/20 0.48
ADRA1B P35368 1/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
RAB9A P51151 1/20 0.48
CYP1A2 P05177 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041959 1.00 TSHR (0.54) TSHRMAOBMAOAF2RL3CYP2D6
SCHEMBL924777 0.98 TSHR (0.53) TSHRMAOBMAOAF2RL3CYP2D6
SCHEMBL1767329 0.87 TSHR (0.65) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL791926 0.85 TSHR (0.62) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL17678491 0.85 TSHR (0.51) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL925746 0.84 TSHR (0.54) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL10456732 0.84 TSHR (0.54) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL3721964 0.84 TSHR (0.57) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL6253038 0.84 HTR1A (0.51) TSHRMAOBMAOACYP2D6CYP2C9
SCHEMBL9506155 0.84 TSHR (0.50) TSHRMAOBMAOACYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed
US-20100160349-A1 TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS LOVE CHRISTOPHER JOHN 2010-06-24 US disclosed
US-20100160349-A1 TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS LOVE CHRISTOPHER JOHN 2010-06-24 US disclosed
WO-2006075023-A2 TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 TSHR 4095/4885MAOB 4424/4885MAOA 4567/4885
US-20100160349-A1 TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS GSK3B, GSK3A, GYS2 TSHR 2721/4885MAOB 427/4885MAOA 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.